News Agency
The Times

Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity

  • Written by PR Newswire

The collaboration will accelerate the global development of LAE102, a novel Activin Receptor Type 2 A (ActRIIA) Antagonistic Monoclonal Antibody (mAb) for muscle-preserving weight loss in Obesity

LOS ANGELES, Nov. 20, 2024 /PRNewswire/ -- Laekna, Inc. (2105.HK) ("Laekna"), a global biotech company focused on novel drug development for...

Read more: Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal...

Google Ads Agency Sydney: How to Generate More Qualified Leads With Paid Search

When someone searches Google for a service they need immediately, appearing at the right moment can be extremely valuable. Unlike many traditional marketing channels, paid search can place a business in front of people who are already researching a product... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion